ストックスクリーナーアプリを入手
14.56
8.54%
1.045
前日終値:
$13.52
開ける：
$13.66
24時間の取引高:
332.74K
Relative Volume:
0.69
時価総額：
$1.01B
収益：
$62.71M
当期純損益:
$-112.51M
株価収益率:
-9.6457
EPS:
-1.51
ネットキャッシュフロー:
$-96.01M
1週間 パフォーマンス:
+7.42%
1か月 パフォーマンス:
+19.89%
6か月 パフォーマンス:
+5.72%
1年 パフォーマンス:
+45.00%
1日の値動き範囲:
$13.66
$15.00
1週間の範囲:
$12.77
$15.00
52週間の値動き範囲:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
名前
Zymeworks Inc.
セクター
電話
604-678-1388
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.56 | 1.02B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.34 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.80 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.58 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.17 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.40 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-07 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 再開されました | Wells Fargo | Overweight |
| 2023-01-04 | 繰り返されました | H.C. Wainwright | Neutral |
| 2022-12-20 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
| 2022-05-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-03-15 | 開始されました | Evercore ISI | Outperform |
| 2021-12-10 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Neutral |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-02-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 再開されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-08-06 | 開始されました | SVB Leerink | Outperform |
| 2020-01-10 | 開始されました | Wolfe Research | Outperform |
| 2019-12-09 | 開始されました | JP Morgan | Neutral |
| 2019-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-30 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 開始されました | Stifel | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-05-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 開始されました | Raymond James | Outperform |
すべてを表示
Zymeworks Inc. (ZYME) 最新ニュース
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences - TipRanks
Zymeworks to Report Second Quarter 2025 Financial Results and Ho - GuruFocus
Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire
Zymeworks Sets Q2 Earnings Date, Announces Major Biotech Conference Appearances at BTIG and Stifel - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
What makes Zymeworks Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Zymeworks Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Janney Montgomery Scott LLC Boosts Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks sees $3.62 million stock purchase by EcoR1 Capital - Investing.com Nigeria
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell Small Cap Comp Value Index - MarketScreener
Zymeworks Inc.(NasdaqGS: ZYME) added to Russell 3000E Growth Index - MarketScreener
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Amends Warrant Agreement with EcoR1 Capital - TipRanks
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500 - Kalkine Media
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price - simplywall.st
SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha
Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - Revista ADVFN
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC - Defense World
BNP Paribas Financial Markets Takes $108,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Ameriprise Financial Inc. Sells 15,800 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment - Seeking Alpha
Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks
Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus
Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - Yahoo Finance
Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault
Zymeworks Inc. (NYSE:ZYME) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World
Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks
Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.
TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq
Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World
Zymeworks Inc. (ZYME) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
2.49%
大文字化:
|
ボリューム (24 時間):